Pioneering Virology Company Aims to Develop Functional Cure for Hepatitis B and Treatments for Coronavirus Infections | William H. Collier, CEO, Arbutus Biopharma Corp. 00:10:00

Share On Facebook Share On Twitter

A virology-focused life science company is dedicated to developing proprietary drug candidates for chronic Hepatitis B virus (HBV) and various strains of coronavirus, with a focus on achieving a functional cure for HBV and effective treatments for coronavirus infections. This initiative leverages groundbreaking virology science, an experienced leadership team, and a strong company culture to address significant unmet medical needs in global healthcare.

Recent Videos